• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cingulate Inc.

    7/25/25 4:32:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on July 25, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Cingulate Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   86-3825535
    (State or other jurisdiction of
    incorporation or organization)
     

    (I.R.S. Employer

    Identification No.)

     

    1901 West 47th Place

    Kansas City, KS 66205

    (Address of Principal Executive Offices) (Zip Code)

     

    Cingulate Inc. 2021 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

    Shane J. Schaffer

    Chief Executive Officer

    Cingulate Inc.

    1901 West 47th Place

    Kansas City, KS 66205

    (Name and address of agent for service)

     

    Telephone: 913-942-2300

    (Telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

     

    Steven M. Skolnick, Esq.

    Michael J. Lerner, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, NY 10020

    Telephone: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act, this Registration Statement is filed by Cingulate Inc. (the “Company”) for the purpose of registering additional shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), under the Company’s 2021 Omnibus Equity Incentive Plan, as amended (the “Equity Plan”).

     

    The number of shares of Common Stock available for issuance under the Equity Plan is subject to an automatic annual increase on January 1 of each year beginning in 2022 and ending on (and including) January 1, 2031 in an amount equal to the lesser of (i) five percent (5%) of the outstanding shares of all classes of the Company’s Common Stock (on a fully diluted basis, but rounded to the nearest 1,000 share increment) as of the last day of the immediately preceding fiscal year or (ii) such number of shares determined by the Company’s Board of Directors (the “Evergreen Increase”). An aggregate of 216,250 additional shares of Common Stock are available for issuance under the Equity Plan as a result of the Evergreen Increase on January 1, 2025 (the “Evergreen Shares”).

     

    On June 10, 2025, at the Company’s 2025 Annual Meeting of Stockholders, the Company’s stockholders approved Amendment No. 2 to the Equity Plan to increase the number of shares of Common Stock authorized for issuance under the Equity Plan by 800,000 shares (the “New Shares” and together with the Evergreen Shares, the “Additional Shares”).

     

    The 1,016,250 Additional Shares being registered pursuant to this Registration Statement are of the same class of securities as the 8,033 shares of Common Stock (after giving effect to the Reverse Splits referenced below) registered for issuance under the Equity Plan pursuant to the currently effective Registration Statement on Form S-8 (Registration No. 333-264002) filed on March 30, 2022, the 3,577 shares of Common Stock (after giving effect to the Reverse Splits referenced below) registered for issuance under the Equity Plan pursuant to the currently effective Registration Statement on Form S-8 filed on March 13, 2023 (Registration No. 333-270484), the 9,800 shares of Common Stock (after giving effect to the 2024 Reverse Split referenced below) registered for issuance under the Equity Plan pursuant to the currently effective Registration Statement on Form S-8 filed on April 4, 2024 (Registration No. 333-278511) and the 104,167 shares of Common Stock (after giving effect to the 2024 Reverse Split referenced below) registered for issuance under the Equity Plan pursuant to the currently effective Registration Statement on Form S-8 filed on July 15, 2024 (Registration No. 333-280819) (collectively, the “Prior Registration Statements”). The information contained in the Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E. Any items in the Prior Registration Statements not expressly changed hereby shall be as set forth in the Prior Registration Statements.

     

    All share amounts referenced above and otherwise in this Registration Statement give effect to a 1-for- 20 reverse stock split of the Common Stock effected on November 30, 2023 (the “2023 Reverse Split”) and a 1-for-12 reverse stock split of the Common Stock effected on August 9, 2024 (the “2024 Reverse Split” and together with the 2023 Reverse Split, the “Reverse Splits”).

     

     
     

     

    PART II

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Company with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference :

     

      (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on March 27, 2025;
         
      (b) the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2025, filed on May 8, 2025;
         
      (b) the Company’s current reports on Form 8-K, filed with the Commission on January 7, 2025, January 24, 2025, February 3, 2025, March 4, 2025, April 9, 2025, May 13, 2025 and June 11, 2025   July 22, 2025 and July 25, 2025 (other than any portions thereof deemed furnished and not filed); and
         
      (c) the description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A (Registration No. 001-40874) filed with the Commission on December 3, 2021 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.5 to the Company’s annual report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025.

     

    All documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    Item 8. Exhibits.

     

    Exhibit       Incorporated by Reference
    Number   Exhibit Description   Form   Exhibit   Filing Date
    4.1   Cingulate Inc. 2021 Omnibus Equity Incentive Plan   S-1   10.1   9/27/2021
    4.2   Amendment No. 1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan   8-K   10.1   6/12/2024
    4.3   Amendment No. 2 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan   8-K   10.1   6/11/2025
    5.1*   Opinion of Lowenstein Sandler LLP            
    23.1*   Consent of KPMG LLP            
    23.2*   Consent of Lowenstein Sandler LLP (included in Exhibit 5.1)            
    24.1*   Power of Attorney (included on the signature page)            
    107*   Calculation of Filing Fee Table            

     

    *Filed herewith

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kansas City, State of Kansas on July 25, 2025.

     

      CINGULATE INC.
         
      By: /s/ Shane J. Schaffer
        Shane J. Schaffer
        Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Cingulate Inc., a Delaware corporation, do hereby constitute and appoint each of Shane J. Schaffer and Jennifer L. Callahan as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.

     

    Person   Capacity   Date
             
    /s/ Shane J. Schaffer   Chief Executive Officer and Chairman    
    Shane J. Schaffer   (Principal Executive Officer)   July 25, 2025
             
    /s/ Jennifer L. Callahan   Chief Financial Officer    
    Jennifer L. Callahan   (Principal Financial Officer and Principal Accounting Officer)   July 25, 2025
             
    /s/ Jeffrey S. Ervin        
    Jeffrey S. Ervin   Director   July 25, 2025
             
    /s/ Bryan Lawrence        
    Bryan Lawrence   Director   July 25, 2025
             
    /s/ John A. Roberts        
    John A. Roberts   Director   July 25, 2025
             
    /s/ Peter J. Werth        
    Peter J. Werth   Director   July 25, 2025

     

     

    Get the next $CING alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CLO and CCO Patel Nilay Dahyabhai

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:02:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Patel Nilay Dahyabhai

    3 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CSO Silva Raul R.

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/9/25 6:00:13 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Provides Management Team Update

    Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of Directors of Cingulate Inc. ("Cingulate") announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate's Chief Financial Officer, has been appointed interim CEO to ensure business continuity and operational stability. Ms. Callahan will retain her responsibilities as Chief Financial Officer. Healthcare in

    8/15/25 9:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

    KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinet

    8/6/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301

    KANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee Act) fee waiver from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for lead asset CTx-1301 (dexmethylphenidate HCI) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Granted through the small business waiver provision of the Federal Food, Drug, and Cosmetic Act (FD&C Act),

    7/29/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/22/24 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

    4 - Cingulate Inc. (0001862150) (Issuer)

    9/18/23 6:00:26 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    SEC Filings

    View All

    SEC Form DEF 14A filed by Cingulate Inc.

    DEF 14A - Cingulate Inc. (0001862150) (Filer)

    8/15/25 4:30:24 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Cingulate Inc.

    NT 10-Q - Cingulate Inc. (0001862150) (Filer)

    8/15/25 9:09:25 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cingulate Inc. (0001862150) (Filer)

    8/15/25 9:08:02 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

    Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

    5/27/25 10:05:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

    KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

    2/13/24 6:45:00 AM ET
    $BACK
    $CING
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CING
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

    CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming Medical Meeting CTx-1301 Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., March 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2022, and provided a clin

    3/10/23 4:05:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/30/24 6:00:22 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care